Shares of Eli Lilly ( LLY -10.79%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ...

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged net income of $2.76 billion, or $3.06 a share, up ...